CN105853467A - Purpose of Lactobacillus reuteri GMNL-263 for preparing hypolipidemic composition - Google Patents
Purpose of Lactobacillus reuteri GMNL-263 for preparing hypolipidemic composition Download PDFInfo
- Publication number
- CN105853467A CN105853467A CN201510027133.2A CN201510027133A CN105853467A CN 105853467 A CN105853467 A CN 105853467A CN 201510027133 A CN201510027133 A CN 201510027133A CN 105853467 A CN105853467 A CN 105853467A
- Authority
- CN
- China
- Prior art keywords
- purposes
- gmnl
- composition
- cholesterol
- lactobacillus reuteri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a purpose of Lactobacillus reuteri GMNL-263 for preparing a hypolipidemic composition. A preservation number of the Lactobacillus reuteri GMNL-263 is BCRC 910452 and CCTCC M 209263, and the Lactobacillus reuteri can specifically inhibit the expression of related genes for synthesis of inflammation factors and lipid as well as can increase the expression of cholesterol metabolism-related genes; and thereby, the Lactobacillus reuteri GMNL-263 can be used for preparing the hypolipidemic composition, and reaches the purpose of treatment of hyperlipidemia.
Description
Technical field
The invention relates to a kind of lactobacillus reuteri GMNL-263 for preparing the purposes of blood-fat reducing composition,
Refer in particular to the composition containing lactobacillus reuteri and there is suppression tumor necrosis factor α (TNF-α), fatty acid synthetase
(FAS), cholesterol modulation element conjugated protein (SREBP-1c) gene expression, and promote LDL receptor
(LDLR) and the ability of cholesterol 7α-hydroxylase (CYP7A1) gene expression, the purpose of blood fat is reduced.
Background technology
Owing to eating the factors such as probability increase and diet sophistication outside modern, the calorie intake causing modern is too much, makes
Fat is hoarded in vivo, the most easily has the situation of hyperlipemia.Pointing out according to research, hyperlipemia is the most easily led
Cause fatty liver or atherosclerotic artery sclerosis, be also cause hypertension, heart disease, headstroke, diabetes, artery sclerosis,
The significant risk factor of kidney trouble etc..It follows that how to maintain blood fat to be less than normal range (NR) to reduce painstaking effort
The attack rate of the diseases such as pipe, it has also become the emphasis that modern is deeply concerned.
At present using natural extract as primary raw material more and more to be loved by consumer in the way of reaching blood fat reducing function,
Such as TaiWan, China patent the I387460th " a kind of has the multiple-effect compound food downgrading blood pressure and blood lipoid and fatty liver
Combination and the extraction method of each material thereof " i.e. disclose four materials (balsam pear, green alga, soybean protein, Radix Glycyrrhizae) of extraction
The method of PPAR active component and proportion of composing, it was demonstrated that it has the effect improving blood sugar, blood fat, and has into one
Step improves new effect of fatty liver；TaiWan, China patent the I441643rd " adjusts blood fat and protects cardiovascular combination
Thing " disclose one and adjust blood fat and protect cardiovascular composition, it is solid that it comprises compound Rohoodiola powder, red colouring agent for food, also used as a Chinese medicine, plant
Alcohol, natto and Cobastab group；Wherein, compound Rohoodiola powder: red colouring agent for food, also used as a Chinese medicine and phytosterol: natto and Cobastab
The predetermined ratio of group is 54～79:14～39:7～32 percentage by weights；Wherein this compound Rohoodiola powder comprise Lip river god,
Rhodiola root, pellet, mulberry leaf, cassia seed, lotus leaf, celestial short, bristly hair or beard, Radix Glycyrrhizae or a combination thereof；And TaiWan, China patent I440465
Number " extracting mixture and medical composition thereof in order to the Chinese herbal medicine of reducing blood lipid " discloses a kind of Chinese herbal medicine in order to reducing blood lipid
Extracting mixture, it comprises: percentage by weight is the longleaf luckyweed flower extract of 33.4～77.7%；Percentage by weight is
11.14～the wilsonii extract of 33.3%；And the Chinese yam extract that percentage by weight is 11.14～33.3%；And disclose
A kind of medical composition in order to reducing blood lipid, it comprises above-mentioned Chinese herbal medicine extraction mixture and pharmaceutically acceptable
Adjuvant；But, natural extract easily there are not clear or organic solvent residual the anxiety of composition and considers.
Probio (Probiotics) for contribute to the enteron aisle bacterium improving host's (such as animals or humans) enteral microecological balance,
Mainly can divide into bacterium and the big class of saccharomycete two, wherein bacterium class can be sub-divided into again Bacillus acidi lactici (Lactobacilli)
And bacillus bifidus (Bifidobacterium) two kinds.Studied at present point out probio except immunity-regulating ability and
Outside enteron aisle health care, also contribute to the healthy supporting functions such as pre-anti-cancer；Furthermore, refering to TaiWan, China patent I355939
Number " probiotic strain GM-263 (ADR-1) for the composition of kidney fibrosis treating diabetes initiation and application thereof ",
Applicant in this case discloses the combination of the kidney fibrosis that a kind of probiotic strain GM-263 (ADR-1) is caused in treatment diabetes
Thing and application thereof, it is to utilize the lactobacillus reuteri GM-263 (ADR-1) of effective content (deposit number is BCRC
910452), manufacture the composition of the kidney fibrosis that treatment diabetes cause, thereby reduce glycated hemoglobin dense with blood sugar
Degree, makes body weight and kidney return multiple normal range (NR), more can be by the message pathway of selectivity suppression JAK2/STAT1
And the expression of suppression kidney fibrosis related protein, and then the kidney fibrosis that effectively treatment diabetes cause；Thus may be used
Knowing, probio also has the effect adjusting blood sugar, improving renal function.
But, according to the studies above fresh discussion less probio in the application of reducing blood lipid, and the regulatory mechanism that may relate to.
In view of this, if can find, there is hypolipemic function probio, and with it as medical composition or raw-food material
Deng product, it is provided that eat to consumer, it will help the health of consumer.
Summary of the invention
Inventor is i.e. in view of above-mentioned existing blood fat-reducing product still has many places disappearance when reality is implemented and used,
Then it is to be assisted a ruler in governing a country by its abundant professional knowledge and practical experience for many years, and is improved, and grind accordingly and create this
Invention.
Main purpose of the present invention is for providing a kind of lactobacillus reuteri GMNL-263 for preparing blood-fat reducing composition
Purposes, it refers to that lactobacillus Lactobacillus reuteri GMNL-263 (being called for short GMNL-263) has suppression and inspires
The scorching factor and lipid synthesis related gene, and promote the ability of cholesterol metabolic related gene expression, may be used to reduce blood
Fat reaches to treat the purpose of hyperlipemia.
In order to reach above-mentioned enforcement purpose, the present invention provide a kind of probio for preparing the purposes of blood-fat reducing composition,
Wherein probiotic strain is that (deposit number is BCRC to lactobacillus reuteri (Lactobacillus reuteri GMNL-263)
910452 and CCTCC M 209263), it is selectivity suppression and the expression of lipid synthesis related gene, and promotes
The expression of cholesterol metabolic related gene, to reduce blood fat.
In one embodiment of the invention, lipid synthesis related gene is fatty acid synthetase (fatty acid synthase；
And cholesterol modulation element conjugated protein (sterol regulatory element binding protein-1 FAS)；
SREBP-1c)；Cholesterol metabolic related gene system LDL receptor (LDL receptor；And courage is solid LDLR)
Alcohol 7 α-hydroxylase (cholesterol 7 α-hydroxylase；CYP7A1)；Inspire scorching factor system tumor necrosis factor α
(tumor necrosis factor alpha；TNF-α).
In one embodiment of the invention, lactobacillus reuteri (such as its dead bacterium) can be used for preparing medical composition, drink
Food fill-in, food or its constituent；Wherein, medical composition comprises pharmaceutically acceptable supporting agent, and in can
Formulation for oral administration medicine supplying.
In one embodiment of the invention, blood fat function can be reduced containing lactobacillus reuteri composition and include that reduction serum is total
Cholesterol, serum low-density LP, Serum MDA, total cholesterol of liver and liver MDA；Furthermore containing sieve
Yi Shi lactobacillus composition also can improve enteron aisle bacterium phase further.Accordingly, the composition containing lactobacillus reuteri can be effective
Adjusting blood fat makes it reply normal range (NR), reaches to treat effect of hyperlipemia (hyperlipidemia).
Accompanying drawing explanation
Fig. 1: schematic appearance is dissected in the abdominal cavity of each group animal used as test.
Liver organization mRNA gene expression amount is affected by Fig. 2: GMNL-263 heat-killed bacterium.
Adipose tissue mRNA gene expression amount is affected by Fig. 3: GMNL-263 heat-killed bacterium.
Enteron aisle bacterium phase change is affected by Fig. 4: GMNL-263 heat-killed bacterium.
Detailed description of the invention
Advantage in the purpose of the present invention and structure function thereof, will according to accompanying drawing and coordinate specific embodiment to be explained,
So that reader the present invention can be had deeper into and concrete understanding.
The present invention provides a kind of probio for preparing the purposes of blood-fat reducing composition, and wherein probiotic strain is Luo Yishi breast
Bacillus Lactobacillus reuteri GMNL-263 (be called for short GMNL-263) (deposit number be BCRC 910452 with
CCTCC M 209263), it is that selectivity suppression promotees inflammatory factor and the expression of lipid synthesis related gene, and promotes
The expression of cholesterol metabolic related gene, to reduce blood fat；Wherein lipid synthesis related gene for example, aliphatic acid
Synzyme (fatty acid synthase；And cholesterol modulation element conjugated protein (sterol regulatory element FAS)
binding protein-1；SREBP-1c)；Cholesterol metabolic related gene for example, LDL receptor (LDL
receptor；And cholesterol 7α-hydroxylase (cholesterol 7 α-hydroxylase LDLR)；CYP7A1)；Inspire scorching because of
Son for example, tumor necrosis factor α (tumor necrosis factor alpha；TNF-α).Accordingly, containing Luo Yishi breast bar
The composition of bacterium is applicable to the preparation treatment medical composition of high fat of blood, diet supplement, food or its group composition, with
Reach the purpose of reducing blood lipid.
Composition described herein can include, but are not limited to: food, drink, healthy food, drinking water for animals additive,
Animal feed additive, animal are used and the mankind are suitable for this by medical composition, food additives, beverage additives etc.
Bright application form.
Term " pharmaceutically acceptable " means that material or composition must be compatible with other compositions of composite, and to trouble
Person is harmless；The most pharmaceutically acceptable supporting agent (pharmaceutically acceptable vehicle) can comprise one or many
Kind selected from following reagent: solvent (solvent), emulsifying agent (emulsifier), suspending agent (suspending agent),
Distintegrant (decomposer), adhesive (binding agent), excipient (excipient), stabilization agent (stabilizing
Agent), chelating agent (chelating agent), diluent (diluent), gelling agent (gelling agent), preservative
(preservative), lubricant (lubricant), surfactant (surfactant), and other similar or applicable present invention
Supporting agent.
The composition of the present invention may utilize the technology that one of ordinary skill in the art know in detail, is separated by above-mentioned lactobacillus
Strain, with pharmaceutically acceptable supporting agent, is prepared as being suitable for the formulation of the present composition.Wherein formulation comprises but does not limits
In: solution (solution), emulsion (emulsion), suspension (suspension), powder (powder), lozenge (tablet),
Pill (pill), suck ingot (lozenge), tablet (troche), chewing glue (chewing gum), capsule (capsule) and
Other are similar to or are suitable for the formulation of the present invention.
The present invention " probio " referred to herein refers to lactobacillus reuteri (Lactobacillus reuteri) GMNL-263,
Being preserved in TaiWan, China Foodstuff Industrial Development Inst. of Financial Group Legal Persons, deposit number is BCRC 910452, and preservation
In China typical culture collection center (China Center for Type Culture Collection；CCTCC；China
Luojiashan, Wuchang, Wuhan City, Hubei Province), deposit number is CCTCC M 209263.
Aforesaid probio GMNL-263 may utilize prior art, such as, filter out from the intestines and stomach of normal adults
Candidate strain, and utilize existing qualification bacterial classification method, such as utilize 16S rDNA sequence analysis and commercially available qualification bacterium
Planting the commodity of physio-biochemical characteristics, identifying probiotic strain is lactobacillus reuteri GMNL-263, holds and the most separately goes to live in the household of one's in-laws on getting married at this
State；The present invention mainly assessment lactobacillus Lactobacillus reuteri GMNL-263 (being called for short GMNL-263) heat is killed
Dead bacterium is for regulating effect of blood fat.
The preparation of the heat-killed bacterium of GMNL-263: lactobacillus reuteri (Lactobacillus reuteri GMNL-263) preserves
In Jingyue Biological Science and Technology Co., Ltd.'s fungi preservation storehouse.The reference culture Lactobacillus of freezing tubule will be stored in
Reuteri GMNL-263 is inoculated in MRS culture medium, cultivates 18～36 hours at the incubators of 37 ± 1 DEG C.Afterwards will
After the concentration of yeast-like fungi liquid, high temperature is utilized to carry out heat-killed bacterium.Finally, add protective agent and carry out freeze-drying,
It is fabricated to every gram of Lactobacillus reuteri GMNL-2632 × 1010Cells heat-killed bacterium bacterium powder.
Additionally, by following specific embodiment, can prove further the present invention can the scope of actual application, but be not intended to
Limit the scope of the present invention in any form.
First, 6 week old from breast malet strain male hamster purchased from TaiWan, China National Laboratory Animal center (Taibei,
Taiwan), raise in plastic cement rearging cage, often group 8, totally 32.Control day night circulation in 12 hours, relative humidity
60%, room temperature 23 ± 1 DEG C, freely drink water and feed.Animal used as test, after 1 week adjust, carries out experiment packet,
And proceed by formally experiment in 12 weeks.
Animal used as test is divided into four groups:
1. chow diet group (Control): give chow diet feeding RO water every day, continues 12 weeks；
The highest grease feed group (HFD): give high grease feed feeding RO water every day, continues 12 weeks；
3.GMNL-263 heat-killed bacterium low dose group (HFD+GMNL-263 (L)): make disease 4 through high grease diet induced
Zhou Hou, then feeding GMNL-263 every day heat-killed bacterium low dosage (4 × 109Cell) 8 weeks；
4.GMNL-263 heat-killed bacterium high dose group (HFD+GMNL-263 (H)): make disease through high grease diet induced
After 4 weeks, then feeding GMNL-263 every day heat-killed bacterium high dose (2 × 1010Cells) 8 weeks.
High grease feed formula: high grease feed formulation method is with reference to existing regulation blood fat function experimental technique and draft
High-calorie feed formula, modified based on becoming mouse chow diet formula, added anhydrous butter oil and salad oil
After, there are 4 DEG C of preservations in ice.Normal diet and high lipid food, feed formula describes in detail such as table one:
Table one
| Composition (g/kg) | Normal diet group feed | High lipid food (HFD) |
| Casein (Casein) | 200 | 232 |
| Cystine (L-Cystine) | 3.0 | 3.0 |
| Methionine (DL-Methionine) | -- | 3.5 |
| Cornstarch (Corn Starch) | 397.48 | 137 |
| Maltodextrin (Maltodextrin) | 132 | 150 |
| Sucrose (Sucrose) | 100 | 162.58 |
| Cellulose (Cellulose) | 50 | 50 |
| Cholesterol (Cholesterol) | -- | 1.9 |
| Comprehensive mineral matter (Mineral Mix) (AIN-93) | 35 | 40.60 |
| Calcium monohydrogen phosphate (Calcium phosphate dibasic) | -- | 4.64 |
| Multi-vitamin (Vitamin Mix) (AIN-93) | 10 | 16.24 |
| Choline (Choline Bitartrate) | 2.5 | 5 |
| tert-butylhydroquinone | 0.014 | 0.04 |
| Salad oil (Soybean oil) | 70 | 40 |
| Lard (Lard) | -- | 153.5 |
After the experiment flow of 12 weeks, sacrifice each group of animal used as test, and take out tissue and carry out every analysis, four groups
Exterior case is dissected as shown in Figure 1 in the abdominal cavity of animal used as test.
Embodiment one: analyze serum, liver and the biochemical values content of ight soil
Serum biochemistry value is analyzed: detection project is respectively lipid concentration in blood, including triglyceride (TG), total courage
Sterol (T-CHO), HDL-C (HDL-CHO) and LDL-C (LDL-CHO),
Above-mentioned detection project is all trust TaiWan, China National Laboratory Animal center analysis.
MDA (malonaldehyde, MDA) content analysis in blood: utilize commercially available set group TBARS Assay Kit
(Cayman) measuring mda content in serum, laboratory operating procedures illustrates with reference to manufacturer, finally at wavelength 530nm
Under the conditions of measure light absorption value with disc type spectroanalysis instrument, calculate the containing of cells in sample hormone with standard concentration curve
Amount.
Liver and ight soil lipid analysis: take 0.1g and analyze tissue, in 1ml chloroform-methanol (v/v=2:1) solvent
Middle homogeneous.Filtrate after filtration contains the analysis most lipid of tissue, with chloroform-methanol (v/v=2:1) solvent
Quantitative to 5ml, entrust south, Taiwan Province, China Shan Hua district the analyzed triglyceride of light pathological examination and total courage solid
Alcohol content.
Statistical analysis: each reality is tested in data acquisition analysis of variance (one-way analysis of variance, ANOVA)
Test and between group, whether have significant difference；Wherein asterisk " * " represents that this group has compared to high grease feed group (HFD)
There were significant differences (p < 0.05).
Result refers to table two, observes the heat-killed bacterium of GMNL-263 to lipids in serum changes of contents, it is determined that regulation
The index of blood fat effect；Result shows, compared to high grease feed group, feeding GMNL-263 heat-killed bacterium height agent
Amount group substantially reduces 23% serum total cholesterol content (T-CHO) and reduces Serum MDA (MDA) generation, and three acid
Glyceride (TG), LDL-C (LDL-CHO), HDL-C (HDL-CHO),
LDL-CHO/HDL-CHO ratio and HDL-CHO/T-CHO ratio are all without significant difference.
Furthermore triglyceride (TG), T-CHOL (T-CHO) and MDA (MDA) contain in detection liver and ight soil
Amount, result is as shown in Table 2；Liver organization part, compared to high grease feed group, the heat-killed bacterium of GMNL-263 is high
Dosage group reduces by 10% triglyceride content and reduces the generation of liver MDA；Reviewing, total cholesterol of liver content is then
No significant difference.Ight soil part, compared to high grease feed group, GMNL-263 heat-killed bacterium high dose group then promotes
110% triglyceride content and 93% total cholesterol level.
It can thus be appreciated that the heat-killed bacterium of GMNL-263 can promote that cholesterol is excreted by ight soil, and then reduce internal courage
Sterol absorption, reduces internal cholesterol level.
Table two
Embodiment two: analyze the heat-killed bacterium of GMNL-263 to mRNA gene expression amount shadow in liver and adipose tissue
Ring
Utilize RT-PCR mode, detection (I) liver organization and (II) adipose tissue mRNA gene expression amount, detect base
Because being respectively as follows:
1. promote inflammatory factor: be situated between white element-6 (IL-6) and tumor necrosis factor α (TNF-α), and said gene expression can be led
Cause inflammation situation.
2. lipid synthesis related gene: fatty acid synthetase (fatty acid synthase, FAS), cholesterol modulation element
Associated proteins (sterol response element binding protein-1, SREBP-1c), peroxisome proliferation are lived
Change receptor y (peroxisome prolifera proliferator-activated receptor γ, PPAR γ)；Wherein, aliphatic acid
Synzyme (FAS) and cholesterol modulation element conjugated protein (SREBP-1c) gene are relevant with synthetic fatty acid, and peroxide
Compound enzyme body Proliferator-Activated Receptors γ (PPAR γ) is then relevant with fat metabolism acid.
3. cholesterol metabolic related gene: 3-Hydroxy-3-methylglutaryl CoA A reductase
(3-Hydroxy-3-methylglutaryl-coenzyme A reductase, HMG-CoA R), LDL receptor
(LDL-cholesterol receptor, LDLR) and cholesterol 7α-hydroxylase (cholesterol 7 α-hydroxylase,
CYP7A1)；Wherein, 3-Hydroxy-3-methylglutaryl CoA A reductase (HMG-CoA R) is synthetic cholesterol base
Because of, and LDL-cholesterol receptor (LDLR) and cholesterol 7 α-hydroxylase (CYP7A1) is generation
Thank cholesteryl because of.
Statistical analysis: each reality is tested in data acquisition analysis of variance (one-way analysis of variance, ANOVA)
Test and between group, whether have significant difference；Wherein asterisk " * " represents that this group has compared to high grease feed group (HFD)
There were significant differences (p < 0.05).
(I) liver organization mRNA gene expression amount is affected by the heat-killed bacterium of GMNL-263
Refer to Fig. 2, inspire scorching factor section, result display feeding GMNL-263 heat-killed bacterium high dose suppression
TNF-α cytohormone gene expression；Lipid synthesis related gene part, the result display heat-killed bacterium of GMNL-263
High dose suppression FAS and SREBP-1c gene, reviews, and PPAR γ gene is then without significant difference；Cholesterol metabolic
Related gene part, result display GMNL-263 heat-killed bacterium high dose has lifting CYP7A1 and LDLR base
Because of the situation expressed, and HMG-CoA R is without notable change.
(II) adipose tissue mRNA gene expression amount is affected by the heat-killed bacterium of GMNL-263
The mRNA gene expression amount part of adipose tissue, then observe and promote inflammatory factor and the change of lipid synthesis related gene
Change.Result referring again to the TNF-α of Fig. 3, feeding GMNL-263 heat-killed bacterium high dose group inspire scorching gene,
Synthetic fatty acid SREBP-1c gene all has suppressed situation, and GMNL-263 heat-killed bacterium high dose group has work
Change the situation of fat metabolism acid PPAR γ gene.
From above-mentioned experiment, what the heat-killed bacterium of GMNL-263 can suppress liver and adipose tissue inspires scorching gene table
Reach, reduce body lipid peroxide and produce, represent that the heat-killed bacterium of GMNL-263 has anti-inflammatory and anti-oxidant merit
Effect, and then have effect of regulation blood fat.Furthermore also shown by gene expression amount result, GMNL-263 heat-killed bacterium meeting
Aliphatic acid synthesis in suppression liver organization, and promote aliphatic acid and cholesterol metabolic；This phenomenon also has phase at adipose tissue
Like situation, therefore the heat-killed bacterium of GMNL-263 can reduce aliphatic acid and cholesterol in internal accumulation.
Embodiment three: analyzing the heat-killed bacterium of GMNL-263 affects enteron aisle bacterium phase change
Utilize whether RT-PCR mode, the detection heat-killed bacterium of GMNL-263 affect the bacterium phase change in enteron aisle, inspection
Surveying bacterial classification is that double fork lever Pseudomonas (Bifidobacterium) and pathogenic bacteria Clostridium (Clostridium) are at ight soil
In content.
Statistical analysis: each reality is tested in data acquisition analysis of variance (one-way analysis of variance, ANOVA)
Test and between group, whether have significant difference；Wherein asterisk " * " represents that this group has compared to high grease feed group (HFD)
There were significant differences (p < 0.05).
Result refers to Fig. 4, compared to high grease feed group, although the heat-killed bacterium of feeding high dose GMNL-263 without
Significantly reduce pathogenic bacteria Clostridium content, but significantly change probio double fork lever Pseudomonas content.
From above-mentioned enforcement explanation, the present invention with prior art in comparison, the invention have the advantages that
1. the invention demonstrates that lactobacillus reuteri GMNL-263 may be used to reduce blood fat, and its effect is by specially
One property suppression lipid synthesis related gene, and promote the expression of cholesterol metabolic related gene, promote that cholesterol discharges body
Outward, reduce internal cholesterol absorption, and reduce internal cholesterol level, reach the purposes of reducing blood lipid.
2. the invention demonstrates that what lactobacillus reuteri GMNL-263 had suppression liver and an adipose tissue inspires scorching gene
Express, and reduce the ability that body lipid peroxide produces, represent that lactobacillus reuteri GMNL-263 has anti-
Inflammation and anti-oxidation efficacy.
3., compared to the Chinese herbal medicine of complicated component, the probio (lactobacillus reuteri GMNL-263) of the present invention not only may be used
Safeguard intestinal health, have more the effect adjusting blood fat；Therefore, lactobacillus reuteri GMNL-263 is made further
Become blood-fat reducing composition, consumer can be provided more preferably to select.
In sum, the lactobacillus reuteri GMNL-263 of the present invention is used for preparing the purposes of blood-fat reducing composition,
Really can reach desired use effect by above-mentioned disclosed embodiment, and the present invention be not the most disclosed in Shen
Before please, whence proposes application for a patent for invention in accordance with the law.
Above-mentioned taken off accompanying drawing and explanation, only presently preferred embodiments of the present invention, non-for limiting protection scope of the present invention；
All those skilled in the art diagnostic categories under this invention made other equivalence change or modify, all should be regarded as without departing from
The design category of the present invention.
Claims (10)
1. probio is for preparing a purposes for blood-fat reducing composition, and wherein said probiotics strain is Luo Yishi breast
(deposit number is BCRC 910452 and CCTCC M to bacillus (Lactobacillus reuteri GMNL-263)
209263), it is the expression that selectivity suppression promotees inflammatory factor and lipid synthesis related gene, and promotes cholesterol generation
Thank to the expression of related gene, to reduce blood fat.
2. purposes as claimed in claim 1, wherein said lipid synthesis related gene be fatty acid synthetase and courage solid
Alcohol regulating element associated proteins.
3. purposes as claimed in claim 1, wherein said cholesterol metabolic related gene is LDL receptor
And cholesterol 7α-hydroxylase.
4. purposes as claimed in claim 1, wherein said rush inflammatory factor is tumor necrosis factor α.
5. purposes as claimed in claim 1, wherein said composition is medical composition, diet supplement, food
Or its constituent.
6. purposes as claimed in claim 5, wherein said medical composition comprises pharmaceutically acceptable supporting agent.
7. purposes as claimed in claim 6, wherein said medical composition is in the formulation being available for oral administration medicine supplying.
8. purposes as claimed in claim 1, wherein said composition reduces blood fat function and includes reducing the total courage of serum admittedly
Alcohol, serum low-density LP, Serum MDA, total cholesterol of liver and liver MDA.
9. purposes as claimed in claim 1, wherein said composition improves enteron aisle bacterium phase further.
10. purposes as claimed in claim 1, wherein said lactobacillus reuteri GMNL-263 is dead bacterium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510027133.2A CN105853467B (en) | 2015-01-20 | 2015-01-20 | Lactobacillus reuteri GMNL-263 is used to prepare the purposes of blood-fat reducing composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510027133.2A CN105853467B (en) | 2015-01-20 | 2015-01-20 | Lactobacillus reuteri GMNL-263 is used to prepare the purposes of blood-fat reducing composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105853467A true CN105853467A (en) | 2016-08-17 |
| CN105853467B CN105853467B (en) | 2019-07-26 |
Family
ID=56623225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510027133.2A Active CN105853467B (en) | 2015-01-20 | 2015-01-20 | Lactobacillus reuteri GMNL-263 is used to prepare the purposes of blood-fat reducing composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105853467B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107523526A (en) * | 2017-10-17 | 2017-12-29 | 无限极（中国）有限公司 | A kind of lactobacillus reuteri and application thereof |
| CN110205261A (en) * | 2019-05-10 | 2019-09-06 | 湖南菲勒生物技术有限公司 | A kind of breast milk source lactobacillus reuteri lipid-loweringing and the application for adjusting the lipid metaboli rhythm and pace of moving things |
| CN110384719A (en) * | 2018-04-20 | 2019-10-29 | 景岳生物科技股份有限公司 | The L. reuteri strain GMNL-263 and combinations thereof of hypertension can be improved |
| CN112322527A (en) * | 2020-11-03 | 2021-02-05 | 江南大学 | Lactobacillus reuteri capable of intervening metabolic syndrome and application thereof |
| CN113403231A (en) * | 2021-07-08 | 2021-09-17 | 江南大学 | Lactobacillus reuteri CCFM1178 capable of intervening metabolic syndrome and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102274245A (en) * | 2010-06-09 | 2011-12-14 | 景岳生物科技股份有限公司 | Novel lactacidophilus, composition thereof and use thereof in preparation of medicines for relieving diabetes mellitus and complications |
| CN102935092A (en) * | 2010-06-09 | 2013-02-20 | 景岳生物科技股份有限公司 | Novel lactobacilli and composition thereof, and application thereof in preparing medicines used for ameliorating diabetes and complications thereof |
-
2015
- 2015-01-20 CN CN201510027133.2A patent/CN105853467B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102274245A (en) * | 2010-06-09 | 2011-12-14 | 景岳生物科技股份有限公司 | Novel lactacidophilus, composition thereof and use thereof in preparation of medicines for relieving diabetes mellitus and complications |
| CN102935092A (en) * | 2010-06-09 | 2013-02-20 | 景岳生物科技股份有限公司 | Novel lactobacilli and composition thereof, and application thereof in preparing medicines used for ameliorating diabetes and complications thereof |
Non-Patent Citations (1)
| Title |
|---|
| FENG-CHING HSIEH,ET AL: "Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats", 《NUTRITION & METABOLISM》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107523526A (en) * | 2017-10-17 | 2017-12-29 | 无限极（中国）有限公司 | A kind of lactobacillus reuteri and application thereof |
| CN107523526B (en) * | 2017-10-17 | 2020-05-12 | 无限极（中国）有限公司 | Lactobacillus reuteri and application thereof |
| US10968495B2 (en) | 2017-10-17 | 2021-04-06 | Infinitus (China) Company Ltd. | Lactobacillus reuteri and use thereof |
| CN110384719A (en) * | 2018-04-20 | 2019-10-29 | 景岳生物科技股份有限公司 | The L. reuteri strain GMNL-263 and combinations thereof of hypertension can be improved |
| CN110205261A (en) * | 2019-05-10 | 2019-09-06 | 湖南菲勒生物技术有限公司 | A kind of breast milk source lactobacillus reuteri lipid-loweringing and the application for adjusting the lipid metaboli rhythm and pace of moving things |
| CN112322527A (en) * | 2020-11-03 | 2021-02-05 | 江南大学 | Lactobacillus reuteri capable of intervening metabolic syndrome and application thereof |
| CN113403231A (en) * | 2021-07-08 | 2021-09-17 | 江南大学 | Lactobacillus reuteri CCFM1178 capable of intervening metabolic syndrome and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105853467B (en) | 2019-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Granato et al. | Functional foods: Product development, technological trends, efficacy testing, and safety | |
| Alagawany et al. | Potential role of important nutraceuticals in poultry performance and health-A comprehensive review | |
| Camacho et al. | Potential industrial applications and commercialization of microalgae in the functional food and feed industries: A short review | |
| AlFadhly et al. | Trends and technological advancements in the possible food applications of Spirulina and their health benefits: A Review | |
| Leyva-López et al. | Exploitation of agro-industrial waste as potential source of bioactive compounds for aquaculture | |
| Antognoni et al. | Integrated evaluation of the potential health benefits of einkorn-based breads | |
| Khan et al. | Black cumin seeds as phytogenic product in broiler diets and its effects on performance, blood constituents, immunity and caecal microbial population | |
| Ribeiro Pereira et al. | Anticancer and Immunomodulatory Benefits of Taro (Colocasia esculenta) Corms, an underexploited tuber crop | |
| Lee et al. | Effect of Pleurotus eryngii stalk residue on the oxidative status and meat quality of broiler chickens | |
| CN105853467A (en) | Purpose of Lactobacillus reuteri GMNL-263 for preparing hypolipidemic composition | |
| Mat et al. | Coconut palm: food, feed, and nutraceutical properties | |
| TWI695685B (en) | Broth compositions and their use as prebiotics | |
| TWI627959B (en) | Use of lactobacillus reuteri gmnl-263 for manufacturing composition for increasing expression of ldl-r and cyp7a1 in liver in high-fat diet individual | |
| Lin et al. | Plasma lipid regulatory effect of compounded freshwater clam hydrolysate and Gracilaria insoluble dietary fibre | |
| Ahmed et al. | Improving the nutritional quality and shelf life of broiler meat by feeding diets supplemented with fermented pomegranate (Punica granatum L.) by-products | |
| Krepkova et al. | Valuable Hepatoprotective Plants-How Can We Optimize Waste Free Uses of Such Highly Versatile Resources? | |
| Park et al. | Rice bran fermented with kimchi-derived lactic acid bacteria prevents metabolic complications in mice on a high-fat and-cholesterol diet | |
| Zhou et al. | Fabrication of quercetin-loaded nanoparticles based on Hohenbuehelia serotina polysaccharides and their modulatory effects on intestinal function and gut microbiota in vivo | |
| Elwan et al. | The potential role of citrus limon powder as a natural feed supplement to boost the productive performance, antioxidant status, and blood biochemistry of growing rabbits | |
| Koirala et al. | Fermented brewers’ spent grain containing dextran and oligosaccharides as ingredient for composite wheat bread and its impact on gut metabolome in vitro | |
| CN102106895B (en) | Composition with function of regulating blood fat | |
| Shi et al. | Effects of dietary supplementation with Radix Isatidis polysaccharide on egg quality, immune function, and intestinal health in hens | |
| Trabelsi et al. | Effects of supplementation with L. plantarum TN8 encapsulated in alginate-chitosan in broiler chickens | |
| Deng et al. | Effects of grape seed procyanidins on antioxidant function, barrier function, microbial community, and metabolites of cecum in geese | |
| Tao et al. | Postbiotics of Bacillus subtilis LCBS1 have beneficial effects on bullfrogs (Lithobates catesbeianus) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |